Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 65

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 65
---
 patent term disclaimers, adjustments, or extensions). Patent applications in each
of these families are active in multiple jurisdictions, including, the United States, Australia, Canada, Colombia, European Patent Organization,
Israel, New Zealand, and Japan. We are currently exploring potential patent protection strategies for our lead drug candidate, PSX-001.

    Product/Technology
     
    Number of
Applications
     
    Type of Patent
Protection
     
    Applicable
jurisdictions
  
    IHL-42X/Compositions and methods for the treatment of obstructive sleep apnoea (OSA)
     
    12
     
    Standard/utility
     
    AU, CA, CO, EP, IL, JP, NZ, US
  
    IHL-675A/Compositions and methods for the treatment of an inflammatory conditions
     
    16
     
    Standard/utility
     
    AU, CA, CO, EP, IL, JP, NZ, US

We plan to continue to expand our intellectual
property estate by filing patent applications directed to compositions, methods of use, treatment and patient selection, formulations
and manufacturing processes created or identified from our ongoing development of our drug candidates. Our success will depend on our
ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how
related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing
the valid and enforceable patents and proprietary rights of third parties. We seek to obtain domestic and international patent protection,
and endeavor to promptly file patent applications for new commercially valuable inventions.

The patent positions of biopharmaceutical companies
like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent
application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance.
Moreover, many jurisdictions, including the United States, permit third parties to challenge issued patents in administrative proceedings,
which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are
currently pursuing, or may in the future pursue, will issue as patents in any particular jurisdiction or whether the claims of any issued
patents will be enforceable or provide sufficient protection from competitors.

Because patent applications in the United States
and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and since publication of discoveries